Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
2 Months : From Dec 2019 to Feb 2020
By Colin Kellaher
Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Wednesday said it filed with the European Medicines Agency for expanded use of its Spravato nasal spray in adults at imminent risk for suicide.
The drug maker said it is seeking European approval for Spravato as an acute short-term treatment, co-administered with oral antidepressant therapy, for the rapid reduction of depressive symptoms in adults with a moderate-to-severe depressive episode of major depressive disorder who have current suicidal ideation with intent.
The European Commission last month approved Spravato for adults with treatment-resistant major depressive disorder.
Write to Colin Kellaher at email@example.com
(END) Dow Jones Newswires
January 15, 2020 08:10 ET (13:10 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.